| ipilimumab based treatment | ipilimumab alone | ipilimumab based treatment |
| ipilimumab alone | Ipilimumab (10 mg/kg) | ipilimumab plus gp100 | ipilimumab plus SoC |
| mML - (neo)adjuvant (NA) | | | | |
| mML - NA - all population 9 | | | | |
| mML - NA - PDL1 positive 1 | | | | |
| mML - 1st line (L1) | | | | |
| mML - L1 - all population 7 | | | | |
| mML - L1 - BRAF mutant 2 | | | | |
| mML - L1 - BRAF wild 3 | | | | |
| mML - 2nd line (L2) | | | | |
| mML - L2 - all population 11 | | | | |
| mML - L2 - BRAF mutant 1 | | | | |
Comparator:
vs ipilimumab alone; vs gp100; vs placebo plus SoC; vs interferon alpha; vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;